BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response

Authors:

Abstract
No abstract available
Funding Information
  • National Cancer Institute (U01 CA182898, R01 CA222170)

This publication has 54 references indexed in Scilit: